Salestools LogoSalestools
Salestools AI-agenter
Løsninger
Ressourcer
Virksomhed
Priser
Salestools Logo

Salestools

#1 AI-agent til salgsteams og Go-to-Market-teams. Sælg mere, hurtigere, med mindre indsats.

Produkt

  • AI-salgsagenter
  • Intent-data
  • Teknologidata
  • Besøgssporing
  • Co-Pilot
  • Socialt salg

Løsninger

  • Kundeservice
  • E-handel
  • SaaS
  • Enterprise
  • Lille virksomhed

Ressourcer

  • Rapporten
  • Dokumentation
  • API-reference
  • Hjælpecenter
  • Blog
  • Case-studier
  • Webinarer

Virksomhed

  • Om os
  • Karriere
  • Presse
  • Kontakt
  • Partnere

Vores lokationer

  • New York, HQ
  • Bukarest, AI-forskningslaboratorium
  • Zug, Schweiz

© 2025 Salestools. Alle rettigheder forbeholdes.

Datavilkår & sikkerhedPrivatlivspolitikServicevilkår
Alle systemer operationelle
Salestools LogoSalestools
Salestools AI-agenter
Løsninger
Ressourcer
Virksomhed
Priser
Back to The Report
Fundraising

Ginkgo Bioworks

Ginkgo Bioworks Raises $350M in Series E

2008
Founded
700+
Employees
27 Drydock Avenue, Boston, MA 02210
Updated November 11, 2024
2 min read

Quick Facts

Ginkgo Bioworks Raises $350M in Series E


Ginkgo Bioworks has successfully raised $350M in a Series E at a $4.9B valuation led by Baillie Gifford, General Atlantic, Cascade Investment, T. Rowe Price, Viking Global Investors.


Company Overview


Ginkgo Bioworks is a Biotech company headquartered in 27 Drydock Avenue, Boston, MA 02210, founded in 2008 with 700+ employees.


Organism engineering platform


Fundraising Details


  • Amount Raised: $350M
  • Round Type: Series E
  • Valuation: $4.9B
  • Date: 2024-11-11
  • Investors: Baillie Gifford, General Atlantic, Cascade Investment, T. Rowe Price, Viking Global Investors

About Ginkgo Bioworks


Organism engineering platform The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 27 Drydock Avenue, Boston, MA 02210
  • Founded: 2008
  • Team Size: 700+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in Ginkgo Bioworks's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Ginkgo Bioworks's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $4.9B valuation marks an important milestone for Ginkgo Bioworks, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, Ginkgo Bioworks is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-11-11. For more information about Ginkgo Bioworks, visit their headquarters at 27 Drydock Avenue, Boston, MA 02210.

Topics

Fundraising(2912)BiotechSeries EGinkgo Bioworks

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news

Related Company Reports

Fundraising
Harvey AI

Harvey AI Raises $160 million in Series F

Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•160 million
Fundraising
7AI

7AI Raises $130 million in Series A

7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•130 million
Fundraising
TRIANA Biomedicines

TRIANA Biomedicines Raises $120 million in Series B

TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.

Market Intelligence Team
Market Intelligence Team
Dec 3, 2025
0 min read•120 million